Bacterial antigens (A61K39/02)

Production and application of bacterial histamine // 2628536
FIELD: medicine.SUBSTANCE: method for selecting a probiotic lactic bacterial strain for use in the local production of histamine in a mammal is provided. A product and composition for the local production of histamine in a mammal containing a lactic acid bacterial strain having an active histidine operon and capable of producing histamine is proposed for use in the treatment and/or prevention of inflammatory conditions.EFFECT: local production of histamine in a mammal by selecting certain strains of lactic acid bacteria.13 cl, 9 dwg, 2 tbl, 5 ex

Antibacterial composition for prevention or treatment of hospital infections (versions), bacteriophage stamps used to obtain such composition // 2628312
FIELD: biotechnology.SUBSTANCE: composition includes 7 strains of bacteriophage, each represented by a combination of bacterial phagolysates filtrates with lytic activity of at least 10-4 according to Appelman concerning test strains and isolated bacterial isolates, as well as target additives in an amount of 0.01±99.99 wt % of composition weight. At that, Staphylococcus aureus phagolysate filtrate obtained using the Staphylococcus aureus SCH1 bacteriophage strain, deposited in the collection of FBIS SSC PVB of Rospotrebnadzor under number Ph-105, Staphylococcus aureus phagolysate filtrate obtained using the Staphylococcus aureus SCH111 bacteriophage strain, deposited in the collection of FBIS SSC PVB of Rospotrebnadzor under number Ph-95, Klebsiella pneumoniae phagolysate filtrate, obtained using the Klebsiella pneumoniae KPV15 bacteriophage strain, deposited in the collection of FBIS SSC PVB of Rospotrebnadzor under number Ph-90, Klebsiella pneumoniae phagolysate filtrate, obtained using the Klebsiella pneumoniae KPV811 bacteriophage strain, deposited in the collection of FBIS SSC PVB of Rospotrebnadzor under number Ph-91, Pseudomonas aeruginosa phagolysate filtrate, obtained using the PA5 Pseudomonas aeruginosa bacteriophage strain, deposited in the collection of FBIS SSC PVB of Rospotrebnadzor under number Ph-88, Pseudomonas aeruginosa phagolysate filtrate, obtained using the Pseudomonas aeruginosa PA10 bacteriophage strain, deposited in the collection of FBIS SSC PVB of Rospotrebnadzor under number Ph-89, Acinetobacter baumannii, phagolysate filtrate, obtained using the Acinetobacter Baumannii AM24 bacteriophage strain, deposited in the collection of FBIS SSC PVB of Rospotrebnadzor under number Ph-106. The composition version also contains Acinetobacter baumannii phagolysate filtrate, obtained using the Acinetobacter baumannii AP22 bacteriophage strain, deposited in the collection of FBIS SSC PVB of Rospotrebnadzor under number Ph-42. The appropriate bacteriophage strains are also proposed. Nucleic acid molecules corresponding to the genome of the said bacteriophages are also proposed.EFFECT: expanded range of products containing highly selective natural antibacterial components as the main active ingredient, ensured biological stability and activity of bacteriophages in the agent composition, the composition has a low risk of toxic and side effects, allows to expand versions and methods of practical application of the agent containing bacteriophages, provides storage stability and application efficiency over a wide temperature range.28 cl, 1 dwg, 4 tbl, 24 ex
Haemophilus influenzae spb strain type b - highly active producer of capsular polyribosylribitolphosphate polysaccharide // 2624014
FIELD: biotechnology.SUBSTANCE: Haemophilus influenzae SPB strain type b, which is a highly active producer of capsular polyribosylribitolphosphate polysaccharide, is deposited in the National Collection of Pathogenic Microorganisms and Cell Cultures "GKPM - Obolensk" under number B-7884. The invention provides polyribosylribitolphosphate synthesis, 250-300 mcg/ml.EFFECT: minimum cultivation time.1 dwg, 1 tbl, 2 ex
ethod for hyperimmune serum preparation for farm animals necrobacillosis treatment and prevention // 2622746
FIELD: biotechnology.SUBSTANCE: method involves hyperimmunization of producer-oxen with a formalin-inactivated antigen isolated from the Fusobacterium necrophorum "0-1" VIEV production strain. The antigen is obtained by cultivation of the Fusobacterium necrophorum "0-1" VIEV production strain. Further, the culture liquid is subjected to ultrafiltration with a pore size of 13-20 kDa, 8-10% of Fusobacterium necrophorum "0-1" VIEV strain bacterial mass is added to the ultrafiltrate to Fusobacterium necrophorum "0-1" VIEV content of 1.5-2.0 billion of cells in 1 cm3, sodium salt of succinate chitosan is added at a final weight concentration of 0.5-1.5%. Inactivation is perfomed using with formalin, taken at a final concentration of 0.3-0.4% for 12-14 days at 37-38°C. Then, the resulting antigen is sorbed on 10-15% aluminium hydroxide in a glycol buffer with pH of 8.4-8.6, taken at a final concentration of 1.8-2.0%. Hyperimmunization of producer-oxen is first carried out with a vaccine to prevent farm animals necrobacteriosis at a dose of 0.4-0.6 ml/animal, then 4-5 weeks later - with the antigen obtained by the method described above at the rate of 1.5-2.0 ml of antigen per 100 kg of animal body weight, at first once, intradermically to the pre-laryngeal inguinal lymph node, together with the oil adjuvant, taken at a weight ratio of 1:0.8-1.0 to the antigen. Then twice with an interval of 5-7 days 0.5-0.6 ml of antigen per 100 kg of animal body weight is injected intradermally, first to the right pre-lobular and left inguinal lymph nodes, then to the left progloidal and right inguinal lymph nodes.EFFECT: method allows to obtain high quality serum foranimals necrobacillosis prevention and treatment.4 ex

Immunogenic compositions of multiple antigen presentation, methods and applications relating thereto // 2619176
FIELD: biotechnology.SUBSTANCE: immunogenic composition against one or more polysaccharide antigen, peptide antigen or polypeptide antigen comprises at least one antigenic polysaccharide, at least one peptide or polypeptide antigen and at least one complementary affinity molecules pair. At that, the first affinity molecule is associated with at least one antigenic polysaccharide, and the complementary affinity molecule is associated with at least one peptide or polypeptide antigen, wherein the said first affinity molecule binds to the complementary affinity molecule for the compound of peptide or polypeptide antigen and a polysaccharide antigen.EFFECT: invention allows to induce both humoral and cellular immune responses to one or multiple antigens simultaneously.20 cl, 40 dwg, 4 tbl, 4 ex
ethod of improving efficiency of emergency prevention of experimental melioidosis // 2618425
FIELD: medicine.SUBSTANCE: invention relates to medicine, particularly to microbiology, and can be used in emergency prevention of experimental melioidosis infection. Method comprises combined administration of imunofan immunomodulator and a doxycycline antibiotic to an animal. The imunofan is administered to white mice twice intraperitoneally in a dose of 0.06 mcg per 1 day before and the following days after infection with 5LD50 virulent strain of Burkholderia pseudomallei C-141, and doxycycline is used for 3 days after infection in amount of 2 mg per day, hypodermally. Survival indices of animals are calculated for 30 days after infection with determination of the percentage of surviving mice and the average life of dying mice.EFFECT: invention provides emergency prevention of experimental melioidosis in animals.3 tbl, 3 ex

Treatment or prevention of infection // 2617399
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, namely to dentistry, and concerns kit for treating diseases or conditions associated with presence of P. gingivalis in oral tissue in individual, involving: (i) composition containing an immunogen, which causes immune response against P. gingivalis; (ii) composition containing agent selected from anti-inflammatory agent for oral tissue inflammation reduction in individual and/or antimicrobial agent for removal of microorganisms or their fragments from individual's oral cavity tissues, and (iii) instructions for use (i) and (ii) in treating disease or condition associated with presence of P. gingivalis in oral tissue in subject by administering (ii) before (i). Method of treating disease or condition associated with presence of P. gingivalis in oral tissue in individual is also disclosed.EFFECT: group of inventions provides reducing rate of occurrence or severity of disease or said pathological condition in individual.20 cl, 7 dwg, 9 tbl, 23 ex

Immunostimulating oligodeoxynucleotides // 2615457
FIELD: biotechnology.SUBSTANCE: present invention relates to biotechnology. Immunostimulating methylated CpG-oligodeoxynucleotide, expression vector containing it, vaccine for preventing or controlling infectious disease in poultry, containing above oligodeoxynucleotide and/or expression vector and immunological amount of antigen component extracted from pathogenic for bird virus or microorganism, as well as application of oligodeoxynucleotide as medicinal agent and for prevention of infection in birds are disclosed.EFFECT: proposed oligodeoxynucleotide has high immunomodulatory action and can be used in veterinary as effective immunostimulating component in vaccines against infectious diseases of birds together with antigen component, extracted from virus or microorganism pathogenic for bird.29 cl, 32 dwg, 3 tbl, 24 ex

Combined vaccine pcv/mycoplasma hyopneumoniae // 2615443
FIELD: biotechnology.SUBSTANCE: present invention relates to biotechnology. There are presented polyvalent immunogenic composition containing combination of soluble part of whole cell preparation of Mycoplasma hyopneumoniae (M. hyo) and antigen of porcine circovirus type 2 (PCV2), wherein soluble part of whole cell preparation of M. hyo is free from Ig G and from immune complexes consisting of antigen connected to immunoglobulin, and its production method. Invention also discloses method of pig immunization against M. hyo and PCV2 and kit for implementation thereof.EFFECT: soluble part of whole cell preparation of M. hyo free from Ig G and from the immune complexes consisting of antigen connected to immunoglobulin, it is immunogenic and can be efficiently combined with antigens of another pathogen to produce safe immunogenic composition for use in veterinary science. 25 cl, 12 dwg, 25 tbl, 15 ex
Test strain leptospira of interrogans serogroup icterohaemorrhagiae serovar copenhageni for detection of antibodies to l icterohaemorrhagiae // 2607006
FIELD: biotechnology; medicine.SUBSTANCE: invention relates to medical biotechnology and can be used for detection of antibodies to L. icterohaemorrhagiae. Test strain Leptospira interrogans of Icterohaemorrhagiae serogroup copenhageni serovar with evident antigenic and immunogenic properties is deposited in State collection of pathogenic microorganisms and cell cultures "GKPM-Obolensk" under registration number V-7745.EFFECT: invention provides serological diagnosis of leptospirosis, monitoring of distribution of icterohaemorrhaghic leptospirosis among people and among different species of animals.1 cl, 1 tbl, 2 ex

Vaccine against ehrlichia canis // 2603274
FIELD: medicine.SUBSTANCE: invention concerns a vaccine composition. Characterized vaccine composition contains an effective immunizing amount of inactivated Ehrlichia canis (E. canis), as well as a non-polar solvent, which contains a lipophilic adjuvant, E.canis is inactivated by formalin. Non-polar solvent is a system of chloroform solvents. Invention can be used against monocytic ehrlichiosis in dogs.EFFECT: at its administering as the primary vaccine in a patient a protective immune response is formed, which is a minimum humoral response.10 cl, 5 dwg, 18 tbl, 2 ex
ethod of enhancing nonspecific protection factors activity in patients with chronic obstructive pulmonary disease // 2600838
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to clinical immunology, allergology and pulmonology, and can be used for enhancing the activity of nonspecific protection factors in patients with chronic obstructive pulmonary disease (COPD). For this purpose patients with COPD in a state out of aggravation of the disease are once vaccinated against pneumococcal infection with preparation "Prevenar-13".EFFECT: method enables enhancing the activity of nonspecific protection factors due to increased phagocytic index of neutrophils, monocytes, indicator of activity of spontaneous NBT test of neutrophils, indicator of activity of induced NBT test of neutrophils, as well as increasing percentage of NBT-positive leukocytes in the spontaneous test at its safety and availability.1 cl

Immunostimulating preparation possessing anti-tumor activity // 2597837
FIELD: pharmacology.SUBSTANCE: invention refers to pharmacology, namely to a preparation for stimulating anti-tumor immunity or therapy of oncological diseases. Preparation for stimulating anti-tumor immunity or therapy of oncological diseases is characterized by that the main component contains a mixture of native or inactivated corpuscular antigens obtained by at least three culture strains of pale treponema belonging to different antigen groups of the agent. Method for producing the preparation involves preparation of inoculum of at least three strains of culture treponemas, production of biomass of microbes in a liquid nutrient medium, concentration of the obtained microbial suspensions, thermal inactivation of the concentrated native suspensions, their conservation and purification, followed by mixing. Method for stimulating anti-tumor immunity includes parenteral administration of the preparation in a pharmaceutically acceptable amount. Method of oncological diseases therapy includes parenteral administration of the preparation in a pharmaceutically acceptable amount.EFFECT: above described invention expands the range of immunomodulatory agents with anti-tumor activity.19 cl, 1 dwg, 14 tbl, 9 ex

Salmonella vaccine // 2596208
FIELD: veterinary science.SUBSTANCE: group of inventions refers to veterinary science and is intended for protection of birds against salmonella infection. Method of poultry vaccination against Salmonella includes at least one primary introduction attenuated immunogenic composition or vaccine containing pharmaceutically or veterinary-acceptable excipient, thinner or medium and at least one attenuated Salmonella, which is administered to poultry prior to, at least one booster introduction of inactivated immunogenic composition or vaccine containing pharmaceutically or veterinary-acceptable excipient, thinner or medium and at least one inactivated Salmonella, where at least one inactivated Salmonella is selected from Salmonella in groups and at least one attenuated Salmonella is selected from Salmonella D-group according to which primary and boosting administration is performed every 2-18 weeks. Also disclosed is method of poultry vaccination against Salmonella, including at least one primary introduction of inactivated immunogenic composition or vaccine containing pharmaceutically or veterinary-acceptable excipient, thinner or medium and at least one inactivated Salmonella, which is administered to poultry prior to, at least one booster introduction attenuated immunogenic composition or vaccine containing pharmaceutically or veterinary-acceptable excipient, thinner or medium and, at least one attenuated Salmonella, where at least one attenuated Salmonella or, at least, one inactivated Salmonella is selected from Salmonella in groups and at least one attenuated Salmonella or, at least, one inactivated Salmonella is selected from Salmonella D-group according to which primary and boosting administration is performed every 2-18 weeks.EFFECT: group of inventions increases efficiency of protection of birds against salmonella infection.12 cl, 2 dwg, 9 tbl, 6 ex

Liquid vaccine for multiple serogroups of meningococcus // 2595845
FIELD: medicine.SUBSTANCE: group of inventions discloses aqueous immunogenic compositions, which, after introduction to subject, are able to induce immune response, which is bactericidal in respect to, at least serogroup W135 n. meningitidis and prophylactic against disease caused by H. influenzae of type b containing conjugated capsular saccharide antigen of serogroup W135 and conjugated capsular saccharide antigen H. influenzae of type b (Hib); where said capsule saccharide antigen Hib is conjugated with mutant diphtheria toxin CRM197 or tetanus toxoid and saccharide serogroup W135 conjugated with diphtheria toxoid, as well as method of immunisation against bacterial meningitis, involving introduction of said compositions and use thereof for preparing drugs.EFFECT: group of inventions provides wide spectrum protection against infection of serogroup B, as well as total activity against meningococcus serogroup W135.64 cl, 9 tbl
ethod of treating bruxism // 2593344
FIELD: medicine. SUBSTANCE: invention relates to medicine, namely to dentistry, and can be used for treating bruxism. That is ensured by hardware determination tonic masseter straining, detecting among them muscles with pathological hypertonia, injection in each of them standard solution of botulinum toxin A and lantoksa in total a single dose up to 100 UNITS, the following control of efficiency and safety of injected drug owing to further analysis in face skin within a projection of these muscles dynamics of local temperature using infrared thermography and amplitude of potential amplifiers using surface electromyography during 3 weeks. Note here that before injection there is additional visualization with the help of ULTRASOUND muscle with pathological gipertonusom, before injection the solution is heated to + 37 °C, injection is performed in turn in every muscle under ultrasonic navigation, estimate accuracy and correctness injections of ultrasonic imaging localisation, size and shape of medicinal infiltrate appearing in tissues, safety injection is controlled additionally with the help of ULTRASOUND at duration of preservation and resorption postinjection medicamental infiltrate. EFFECT: invention enables recovering the function of masseter muscels and eliminating the myofascial pain syndrome with dysfunction of temporomandibular joint, due to increased accuracy of metering and injection into a local myorelaxant in each muscle with the help of ultrasonic navigation. 1 cl, 1 ex

Ospa chimeric genes, proteins and methods for use thereof // 2583289
FIELD: medicine.SUBSTANCE: invention relates to biochemistry, particularly to a polypeptide capable of inducing a specific immune response against Borrelia bacteria, and a polynucleotide encoding it. Also disclosed are an expression vector comprising said polynucleotide, a host cell containing it and a method of producing a peptide by culturing said host cell. Invention also relates to compositions comprising said polynucleotides or polypeptides for inducing a specific immune response against Borrelia bacteria.EFFECT: invention enables to effectively treat or prevent Borrelia infection or Lyme disease.24 cl, 24 dwg, 9 tbl, 22 ex
ethod of botulinum toxin injection into masticatory muscles // 2575735
FIELD: medicine.SUBSTANCE: area of planned injection is determined in skin of right and left facial part of patient's head by means of thermal imager or by electromyography, after which palpation of soft tissues in the depth of the entire selected area is performed, presence and quantity of sites with higher and painful hardness are detected in it, their localisation, shape, size and volume are specified. The total single dose of botulinum toxin is diluted with solution of 0.9% sodium chloride in volume 2.5 ml in case of the total volume of sites not exceeding drug volume, with application of solution in equal volume in case of larger total volume. Solution of medication is introduced under ultrasound navigation by turns into each solid site of each muscle until its complete infiltration with solution.EFFECT: elimination of increased tension, painfulness of masticatory muscles and recovery of chewing function under conditions, excluding impairment of facial expression, face asymmetry and impairment of chewing function.1 ex

ethod for facial rejuvenation in patients with anatomical and physiological features of facial skeleton // 2571686
FIELD: medicine.SUBSTANCE: method for facial rejuvenation consists in subdermal and intramuscular injections of botulinum toxin type A containing 500 units and diluted in normal saline in the pre-determined points of problem areas.EFFECT: using the inventions allows providing the more effective facial rejuvenation in expression line correction, enables to prolong the clinical results when using minimum effective dosages with no side effects that leads to a harmonious appearance after the botulinum toxin therapy.6 dwg, 3 ex

Emulsion vaccine produced from heated bacterin // 2569457
FIELD: medicine, pharmaceutics.SUBSTANCE: invention concerns a vaccine for preventing an infection caused by at least one of Leptospira, bovine herpes virus, parainfluenza virus and bovine respiratory syncytial virus. The presented vaccine contains heated bacterin Leptospira having the lipase activity of 50% or less as compared to the pre-heating lipase activity of bacterin and maintaining the antigenic activity, and 1-3 live viruses specified in a group consisting of bovine herpes virus, parainfluenza virus and bovine respiratory syncytial virus. The above heating involves Leptospira bacterin heating to temperature 60°C to 70°C for the period of time from 5 to 10 hours.EFFECT: invention enables producing the stable vaccines maintaining the virus infectivity.7 cl, 5 ex

Francisella tularensis 15/23-1δreca strain having reduced reactogenicity for producing live tularemia vaccine and method for production thereof // 2567810
FIELD: chemistry.SUBSTANCE: invention relates to biotechnology and the Francisella tularensis 15/23-1ΔrecA strain, as well as a method of producing same. The described strain is genetically labelled: has only one copy of the iglC gene and a deleted recA gene. The strain is obtained from the Francisella tularensis 15 NIIEG vaccine strain through successive allelic exchange of one of the two copies of the iglC gene then the recA gene on their deleted versions using a suicide vector plasmid, which is inserted into the cell of the strain by transformation followed by collection of F. tularensis strain cells based on a chloramphenicol resistance attribute and further selection of modified strains on a medium with saccharose.EFFECT: invention enables to obtain a strain with reduced reactogenicity and enables use thereof as a live tularemia vaccine.2 cl, 6 dwg, 8 tbl, 12 ex

Gamma interferon inductor // 2564011
FIELD: biotechnologies.SUBSTANCE: exo polysaccharide of bacteria P.nigrifaciens of KMM 156 strain is used as IFN-γ inductor.EFFECT: use of this polysaccharide provides formation of IFN-γ for creation of a new preparation.2 tbl

Recombinant pseudo adenoviral particle producing modified nanoantibodies recognising mycoplasm mhominis, based pharmaceutical composition and method for using it for mycoplasmosis therapy // 2562158
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to molecular immunology, biotechnology and medicine. A pre-modified sequence of an antibody gene is the nucleotide sequence SEQ ID 1. The created recombinant pseudo adenoviral particle activates a complement system of the mammalian immune system. The pharmaceutical composition represents the recombinant pseudo adenoviral particles according to the declared invention, and a pharmaceutically acceptable carrier; when administered into a mammalian organism, it activates the complement system and suppresses mycoplasm M. hominis. A method for mycoplasm M. hominis therapy is implemented by administering a therapeutically effective amount of the created pharmaceutical composition into a mammal in need thereof. The pharmaceutical composition is administered by intravenous injections.EFFECT: created is the recombinant pseudo adenoviral particle based on human being adenovirus genome of serotype 5 containing an expressing cassette with gene insertion of a modified chimeric nanoantibody binding to mycoplasm M hominis, a nucleotide sequence of which is pre-modified by attaching the effector Fc-fragment of immunoglobulin G.5 cl, 6 dwg, 2 tbl, 6 ex

Components of enterococcal cell walls and their antibacterial application // 2559543
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to the field of biotechnology, microbiology and immunology. Described is a polysaccharide of an enterococcal cell wall. The polysaccharide can be applied as an antigen for obtaining vaccines. Also disclosed are: antibody to the said polysaccharide and pharmaceutical compositions for the prevention and therapy of a bacterial infection.EFFECT: claimed group of inventions can be used in medicine.8 cl, 6 dwg

External cow lipopolysaccharide epitope h. pylori // 2558257
FIELD: chemistry.SUBSTANCE: present invention relates to biotechnology and provides a α1,6-glucan-containing compound of Helicobacter pylori. The present invention also discloses a conjugate for inducing immune response against H.pylori, which contains said compound conjugated with a carrier protein. The present invention also discloses an immunogenic composition, use of said composition and a method of inducing immune response against H.pylori using said composition. The present invention also discloses immune serum for neutralising H.pylori in mammals, which is obtained by immunising said mammal with an immunogenic composition containing said immunogenic composition. The present invention discloses an antibody which recognises said α1,6-glucan-containing compound of H.pylori, use of said antibody and a method of inducing complement-mediated bacteriolysis of H.pylori strains which express α1,6-glucan using said antibody.EFFECT: invention improves the effectiveness of immunogenic compositions against Hpylori.27 cl, 8 dwg, 21 tbl, 11 ex
ethod for producing multiplex rickettsial diagnostic preparation // 2557951
FIELD: medicine.SUBSTANCE: method for producing a multiplex Rickettsial diagnostic preparation involves labelling Rickettsia and Coxiella corpuscular antigens with semiconductor colloidal nanoparticles of different fluorescent colours. The Rickettsia prowazekii corpuscular antigens are conjugated with the nanoparticles at a wavelength of red fluorescence (610-670 nm), and the Coxiella burnetii corpuscular antigen - with the nanoparticles at a wavelength of green fluorescence (520-540 nm). The conjugation process takes one hour and is accompanied by constant stirring. The unreacted nanoparticles are removed by Sephadex G-25 gel filtration chromatography. The labelled Rickettsia and Coxiella are combined into a multiplex diagnostic preparation to be used in the immunofluorescent nanoagglutination reaction (IFNAR). The multiplex diagnostic preparation enables detecting the anti-Rickettsia prowazekii and anti-Coxiella burnetii antibodies simultaneously within one IFNAR.EFFECT: method simplifies the procedure of detecting the specific antibodies in human blood serum, reduces the reaction time twice and provides the more specific detection of the immunofluorescent analysis.3 tbl, 3 ex

Live attenuated vaccines // 2556813
FIELD: medicine, pharmaceutics.SUBSTANCE: inventions relate to the field of biotechnology and deal with a method of preventing or treatment of a disease in a subject, caused by a pathogenic organism, by the introduction of a vaccine composition, the vaccine composition and its application. The characterised vaccine composition contains bacteria, attenuated by mutation in a gene, coding the ABC-peptide transporter protein OppD, which can persist in the subject. The claimed inventions can be applied in immunology to obtain and apply vaccines.EFFECT: said mutation makes the coded ABC-peptide transporter protein non-functional.19 cl, 10 dwg, 21 tbl, 5 ex

Combinations of meningococcal factor-h-binding protein and pneumococcal saccharide conjugates // 2555757
FIELD: chemistry.SUBSTANCE: invention relates to biotechnology and immunology and represents an immunogenic composition for the activation of the immune response with respect to pneumococci and/or meningococci, which contains: (i) a mixture of conjugated pneumococcal capsular saccharides; and (ii) two different polypeptides of a factor-H-binding protein antigen (fHBP), but does not contain vesicles of the meningococcus outer membrane. The invention also relates to a method of activating the immune response in mammals with respect to pneumococci and/or meningococci, which includes the introduction of the said composition to a mammal.EFFECT: invention makes it possible to extend the arsenal of combined vaccines with respect to pneumococci and/or meningococci.24 cl, 1 dwg
Vaccine aimed against actinobacillous pleuropneumonia and method of obtaining thereof // 2554812
FIELD: medicine.SUBSTANCE: claimed group of inventions relates to field of veterinary. Claimed are: vaccine, aimed against actinobacillous pleuropneumonia, including lipopolysaccharide in complex with one or more repeats of ApxI, ApxII and ApxIII toxins, separated from bacterial culture and polymyxin to reduce symptoms of endotoxic shock, caused by lipopolysaccharide, method of obtaining such vaccine, application of polymyxin to reduce endotoxic shock symptoms when vaccine is introduced, in which polymixyn is added into vaccine in dose from 2.6 to 60 mcg/ml.EFFECT: claimed group of inventions provides effective means and methods to reduce endotoxic shock symptoms, caused by lipopolysaccharide, when vaccine against actinobacillous pleuropneumonia is introduced to animal.14 cl, 4 tbl, 4 ex

ethod of manufacturing vaccine, associated against pseudomonosis and viral rabbit haemorrhagic disease // 2553557
FIELD: medicine.SUBSTANCE: invention relates to method of manufacturing vaccine, associated against pseudomonosis and viral rabbit haemorrhagic disease. Characterised method includes selection of affected organs from dead rabbits in the period of their disease from local epizootic focus, separation of pure cultures of disease causing agents, for which purpose separate growing of cultures Pseudomonas aeruginosa and virus of rabbit haemorrhagic disease if performed. To obtain causative agent of pseudomonosis, Pseudomonas aeruginosa culture is grown in beef-extract broth with addition of glucose. To obtain virus of haemorrhagic disease, rabbits are infected with virulent virus of rabbit haemorrhagic disease with infection activity not lower than 103 LD 50/cm3. Samples of dead rabbit's liver are taken, its milling and homogenisation performed. Inactivated cultures Pseudomonas aeruginosa and viral rabbit haemorrhagic disease are mixed in equal proportions Solution of aluminium hydroxide is introduced, mixed, packed and sealed.EFFECT: claimed invention makes it possible to manufacture harmless, highly-immunogenic vaccine, stable in storage.1 tbl

Combinations containing serotype 14 pneumococcal saccharide // 2549438
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to medicine and concerns an adjuvant immunogenic composition containing meningococcal lipooligosaccharide (LOS) and serotype 14 pneumococcal capsular saccharide (CS14), wherein CS14 contains tetrasaccharide Galβ1-4GlcNAcβ1-3Galβ1-4Glc, while LOS is free from tetrasaccharide Galβ1-4GlcNAcβ1-3Galβ1-4Glc. The group of inventions also concerns a method for inducing the immune response in a mammal involving administering the above composition.EFFECT: group of inventions provides the stronger immune response to CS14 A as compared to wild-type OMV containing LNnT.15 cl, 4 dwg, 1 ex

ucrofluidic oil-in-water emulsion and vaccine compositions // 2541809
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and represents a vaccine composition for inducing an immune response in animals. The composition contains an antigen and a 40% oil-in-water emulsion diluted to 2.5%, wherein the above 40% oil-in-water emulsion contains 30 vl/vl % of light hydrocarbon non-metabolic oil, 10 vl/vl % of lecithin, 0.6 vl/vl % of sorbitan monooleate, 1.4 vl/vl % of polyoxyethylene sorbitan monooleate; the oil component is dispersed in an aqueous component by emulsification, while the vaccine composition is prepared by a microfluidiser. An average drop size in the composition makes less than 0.3 mcm.EFFECT: composition possesses improved physical characteristics, enhanced immunising action, as well as high safety.10 cl, 20 ex, 17 tbl, 11 dwg

Nutrient culture medium for swine erysipelas strain erysipelothrix rhuisipathie // 2541454
FIELD: biotechnology.SUBSTANCE: nutrient culture medium for swine erysipelas strain Erysipelothrix rhuisipathie refers to general biotechnology and veterinary microbiology. As a nitrogenous nutrition source, the nutrient medium contains a mixture of fish autolysate and alkaline mussel hydrolysate in the following proportions: alkaline mussel hydrolysate 20-50%; fermentation peptone 1%; potassium phosphate 0.3%; sodium phosphate 1.8%; fish autolysate - the rest.EFFECT: method can be used for preparing the microbiological nutrient media for erysipelas strain upstream.
ethod of obtaining of brucellous l-antigen // 2539827
FIELD: biotechnologies.SUBSTANCE: method of obtaining of brucellous L-antigen is performed as follows. The strain Brucella abortus 19 is cultivated in the L-form in the dense nutrient medium prepared on the basis of meat-peptonic hepatic glucose-glyceric agar (1.3-1.5%) with adding of 10-15% normal horse Serum at the temperature 20-22°C within 2-3 days. The culture, obtained in the L-form, is emulsified with 0.5% phenolised normal saline solution, inactivated at the temperature 85-90°C within 60 minutes. The suspension is centrifuged at 3000-5000 rpm within 15-20 minutes and the concentration of brucellas is established at the level 50-60 billion m.k. The obtained antigen is titrated, standardised by specificity and activity. It is used for agglutination test in serum diagnostics of brucellosis.EFFECT: invention allows to minimise the time of antigen preparation and to increase the yield of bacterial mass.4 tbl, 3 ex

Prophylaxis, treatment and diagnostics of infection caused by p.gingivalis bacteria // 2535898
FIELD: biotechnologies.SUBSTANCE: invention describes a composition for induction of immune response against P. gingivalis, which contains an effective amount of one of the above chimeric or hybrid proteins, a prophylaxis method of a state or a disease related to P. Gingivalis, and a method for reduction of incidence or severity of the state or disease related to P. gingivalis with their application. Besides, the invention describes use of the above chimeric or hybrid proteins for determination of antibodies to P. Gingivalis in a biological specimen.EFFECT: invention allows effective induction of immune response against the specified etiologic agent.16 cl, 7 dwg, 4 tbl, 22 ex

Vaccines and vaccine ingredients for microbial cell inhibition // 2528854
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to biochemistry, particularly to a recovered polypeptide which is a biological target for methane-producing cell inhibition, as well as to a recovered polynucleotide which codes this polypeptide. There are disclosed expression vector and cloning vector containing this polynucleotide, and host cells containing the above expression vector. There are described conjugated molecules or fused molecule for methane-producing cell inhibition, as well as antibody or its functional fragment which binds to the above polypeptide. The invention also covers a pharmaceutical composition and methods for inhibiting and identifying the methane-producing cell with the use of the above conjugated molecule or fused molecule and the antibody or its fragment.EFFECT: invention enables inhibiting the methane-producing cell effectively.19 cl, 9 dwg, 6 ex
Wound-healing agent based on strain trichoderma harzianum rifai // 2528065
FIELD: biotechnology.SUBSTANCE: wound-healing agent is a concentrate of the culture liquid of strain Trichoderma harzianum Rifai deposited in the Russian National Collection of Industrial Microorganisms under the number of RNCIM: F-180, as a producer of L-lysine of alpha-oxidase, and can be applied as a wound-healing agent for skin lesions.EFFECT: invention enables to expand the range of means that provide wound healing of skin lesions.1 tbl, 2 ex
Vaccine against lawsonia intracellularis // 2523561
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to medicine, namely to veterinary science, and can be applicable for using a composition for protection against an infection caused by Lawsonia intracellularis. That is ensured by using a non-living composition containing carbohydrate which is also found in living cells of Lawsonia intracellularis in association with an external cell membrane of the above cells. The vaccine is presented in the form applicable for intramuscular introduction, and contains an oil-in-water adjuvant containing oil drops with an average size of 400 nm.EFFECT: using the given non-living composition leads to effective immunisation in intramuscular introduction with using small drops of the oil-in-water adjuvant which provides protection of animals against Lawsonia intracellularis.7 cl, 9 tbl, 4 ex

ethod of prevention of infectious conjunctivitis-keratitis of cattle // 2517119
FIELD: veterinary medicine.SUBSTANCE: method of prevention of infectious conjunctivitis-keratitis of cattle comprises vaccination with vaccine associated against infectious conjunctivitis-keratitis of cattle based on antigens of bacteria Moraxella bovis and herpesvirus type I, while 29-31 days prior to vaccination the immunostimulatory agent "Kerokonvitin" is injected to the animals subcutaneously in the upper third part of the neck at a dose of 0.045-0.055 ml/kg body weight, obtained on the basis of cytotoxic serum from the blood of donor horses by their hyperimmunisation with antigen prepared from tissues of eyes - the conjunctiva and cornea of cattle which had an infectious disease of conjunctivitis-keratitis. Eye tissues of cattle are obtained during slaughtering animals.EFFECT: improving the efficiency of prevention of infectious conjunctivitis-keratitis of cattle, higher immune status of body of animals.3 tbl, 1 ex, 2 dwg
Hafnia alvei bacteria strain, capable of producing thermolabile lt-enterotoxin // 2514656
FIELD: chemistry.SUBSTANCE: invention relates to biotechnology and can be used to produce thermolabile enterotoxin (LT-enterotoxin) and Hafnia alvei anatoxin when producing a vaccine. The strain is deposited in the State Collection of Pathogenic Microorganisms of FBSI Scientific Centre for Evaluation of Medical Products of the Ministry of Public Health and Social Development of Russia under number 294.EFFECT: strain has high capacity for producing thermolabile LT-enterotoxin.1 tbl, 2 ex

ethod of obtaining preparation based on vaccine strain of plague microbe // 2510825
FIELD: chemistry.SUBSTANCE: invention relates to field of biotechnology and deals with method of obtaining preparation based on vaccine strain of plague microbe. Claimed invention includes preparing inoculation native culture of plague microbe, concentration of microbe suspension, preparing vaccine suspension and obtaining dry form of preparation, with process of preparing inoculation culture including cultivation of microbes in liquid nutritional medium in flasks for 48 h at temperature 26…28°C and contibuous aeration with not less than 10 l min-1. with passaged stabilised starting culture, obtained as a result of three successive passages through organism of guinea pigs and mixed with glycerol-lactose-polyglucinum liquid in ratio 2:1; for preparation of vaccine suspension used is optimised in component composition protective drying medium, lyophilisation being carried out with observance of the specified regimen.EFFECT: claimed solution makes it possible to obtain product with higher activity with reduced duration of process of its manufacturing.3 dwg, 6 tbl

ethod of production of protective antigen and protein of s-layer ea1of asporogenous recombinant strain in anthracis 55 δtpa-1spo- // 2492241
FIELD: biotechnology.SUBSTANCE: method includes cultivation of previously prepared culture of the recombinant strain B. anthracis 55ΔTPA-1Spo-. The cell mass is separated using the filtration module with a membrane having a pore diameter of 0.2 mcm. Protein EA1 is extracted from the washed cell mass using a buffer with 1% sodium dodecyl sulfate, and purified by diafiltration using membrane filters and two-stage ion-exchange chromatography on hydroxyapatite. The protective antigen is isolated from the culture filtrate and purified by successive steps of concentration and diafiltration.EFFECT: use of the invention enables to obtain in one processing chain the highly purified antigens of anthrax microbe - protective antigen and protein EA1 needed to create chemical vaccines.3 dwg, 5 ex

ycoplasma hyopneumoniae avirulent adjuvant live vaccine // 2489164
FIELD: medicine, pharmaceutics.SUBSTANCE: presented group of inventions refers to medicine. There are presented a composition containing an immunologically effective amount of the live avirulent strain Mycoplasma hyopneumoniae, and a method of inducing the immune response on Mycoplasma hyopneumoniae, involving the stage of administering the above composition to an animal. What is presented is a method of preventing or relieving an attack of Mycoplasma hyopneumoniae. There are also presented methods of enhancing the immune response on Mycoplasma hyopneumoniae, involving the stages of administering single or double doses of the above composition to the animal.EFFECT: group of inventions is effective to provide the immunity in the animal and to protect from the infection with the virulent strain Mycoplasma hyopneumoniae, thereby reducing a severity and/or preventing the diseases caused by one or more virulent strains Mycoplasma hyopneumoniae.18 cl, 8 tbl, 4 ex

ethod for producing brucellous l-antigen // 2486916
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to veterinary microbiology, immunology, biotechnology, namely to technology of an antigen for diagnosing brucellosis. The method for producing brucellous L-antigen is implemented as follows. The strain Brucella abortus 19 is cultured in the L-form on a solid nutrient medium prepared of meat-peptone liver glucose-glycerol agar (1.3-1.5% agar) with added 10-15% normal horse serum and streptomycin in a dose of 2.5-5.0 Units/ml at 37-38°C for 4-5 days. Then the prepared L-form culture is emulsified by 0.5% phenolised physiological saline; the suspension is inactivated at temperature 85-90°C for 60 minutes, centrifuged at 3000-5000 rpm for 15-20 minutes; the brucella concentration is specified at 50-60 bln microbial cells; the prepared antigen is titred, standartised by specificity and activity. The latter is used for the purpose of an agglutination test in serological diagnosis of brucellosis. The invention enables higher effectiveness and reliability of diagnosing brucellosis by 20-25%.EFFECT: invention may be used for diagnosing brucellosis in carrier animals with persistent changed L-forms of the agent.4 tbl, 3 ex

ethod for increasing antigen immunogenecity of b. pseudomallei antigens in experimental melioidosis // 2483752
FIELD: medicine, pharmaceutics.SUBSTANCE: method comprises immunising the animals with the use of surface melioidosis antigens in the liposomal form, and for the purpose of the additional stimulation of the cell immunity mechanisms, the immunomodulator Bestim is added to cytokines. The stimulant action of the preparations on the immune system is assessed in dynamics of the immune response as shown by the TDTH level and a degree of chemiluminescence response to zymosan of peritoneal macrophages in the immunised mice. The protective properties of the antigens are stated by mortality rates (the percentage of surviving animals and the average life expectancy) after the control infection with the virulent culture of B. pseudomallei. The immunogenic and protective properties of the antigens are substantially increased through the use of the antigen in the liposomal form and the addition of the cell immunity activator Bestim into the immunisation schedule.EFFECT: method shall provide higher immunogenicity of the melioidosis antigens while developing the preparations for specific prevention of melioidosis infection.6 tbl, 2 ex

ethod to produce lypopolysaccharide of plague agent // 2483112
FIELD: biotechnologies.SUBSTANCE: invention may be used for production of antigens, diagnostic and preventive preparations. The method includes preliminary water and salt treatment of bacterial cells with their subsequent lysis by a buffer solution, containing 0.1 M Teis-HCI pH 8.0, 10 mM EDTA, 1% Triton X-100. Destruction with ultrasound is carried out. The untreated extract of LPS is treated with a ferment complex of proteovibrin until the final concentration of 160 mcg/ml and incubated at 37°C, pH 7.8-8.0 for 18 h. Treatment from nucleic acids is carried out by acidification of a sample with an ice acetic acid to pH 3.2-3.4 and their deposition at 5000 g for 30 min.EFFECT: invention makes it possible to improve quality of LPS preparations, to simplify and cheapen methodology, to reduce time of LPS extraction.2 tbl, 2 dwg
ethod for differentiation of strains helicobacter pylori by multilocal vntr-typing // 2482191
FIELD: medicine, pharmaceutics.SUBSTANCE: presented invention refers to medical microbiology, particularly to molecular-genetic typing of the strains Helicobacter pylori. What is presented is a method for differentiation of the strains H.pylori by multilocal VNTR-typing with the PCR involving oligonucleotide primers on VNTR-comprising loci of H.pylori - HpA, HpD, HpE and HpF; the strains H.pylori are differentiated by a number of repetitions in the amplified fragments in each VNTR-comprising locus of H.pylori - HpA, HpD, HpE and HpF that enables genetic typing of the studied strains.EFFECT: what is presented is the method for differentiation of the strains Hpylori by multilocal VNTR-typing.1 tbl, 3 ex

New bacteria causing diseases of poultry and vaccine produced from them // 2481393
FIELD: biotechnologies.SUBSTANCE: new strain of bacteria Pasteurella trehalosi is proposed, where the specified bacteria are positive in respect to beta-haemolysis, positive in respect to oxidase, positive in respect to catalase, negative in respect to urease, positive in respect to nitrates, negative in respect to indole, MacConkey-positive, positive in respect to glucose, positive in respect to saccharose, positive in respect to mannitol, negative in respect to arabinose, negative in respect to cellobiose, positive in respect to xylose, negative in respect to salicin, negative in respect to ornithine, negative in respect to esculin, negative in respect to alpha-fucosidase, positive in respect to beta-galactosidase. Also the strain of bacteria Mannheimia haemolytica is proposed. These bacteria are deposited under registration numbers ATCC No. PTA-3667, ATCC No. PTA-3668, ATCC No. PTA-3669.EFFECT: immunisation of chickens with the purpose to prevent disease caused by above bacteria.7 cl, 22 dwg, 2 tbl, 6 ex

Live attenuated mycoplasma bacterium, vaccine containing it and method for identifying such bacterium // 2473682
FIELD: medicine.SUBSTANCE: Mycoplasma bacterium shows expression lower at least by 25% of one or more one protein specified in a group consisting of piruvate dehydrogenase, enolase, 2-desoxyribose-5-phosphataldolase and ribosomal protein L35. The vaccine containing such strain is applicable for animal vaccination against an infection caused by Mycoplasma bacteria. A method for identifying clones of such bacterium involves: placing an initial population of Mycoplasma bacterium into the attenuation environment to produce a potentially attenuated bacterial population; analysis of separate clones of the potentially attenuated bacterial population in relation to low expression of one or more said proteins; and testing the clones identified as having expression lower at least by 25% of one or more proteins in relation to virulence.EFFECT: invention enables developing an attenuation strategy of Mycoplasma bacteria and may be used for prevention of the diseases caused by such bacterium.16 cl, 1 dwg, 5 tbl, 3 ex
Universal vaccine for treating and preventing lyme disease applicable in human and veterinary science, and method for preparing it // 2472525
FIELD: medicine.SUBSTANCE: invention refers to medicine, and concerns a universal vaccine for treating and preventing Lyme disease to be applied in veterinary science, based on a whole-cell bacterial vaccine or bacterial lysates or purified preparations, containing the three most pathogenic genospecies Borrelia burgdorferi sensu stricto, Borrelia afzelii and Borrelia garinii, each of which simultaneously contains both immunogenic protective proteins of the outer membranes OspA and OspC.EFFECT: invention provides developing the protective immunity against a natural tick-borne infection of the three most pathogenic genospecies Borrelia burgdorferi sensu stricto, Borrelia afzelii and Borrelia garinii.9 cl, 1 ex, 12 tbl
 
2551029.
Up!